On Tuesday, Shares of Campbell Soup Company (NYSE:CPB), lost -2.33% to $46.87.
Campbell Soup Company invites interested shareholders, investors, members of the media and consumers to listen to and view the slides accompanying its fourth-quarter and full-year fiscal 2015 earnings call, which will be webcast live over the Internet on Thursday, Sept. 3, 2015 at 8:30 a.m. EDT.
Campbell Soup Company, together with its auxiliaries, manufactures and markets convenience food products. It operates through U.S. Simple Meals; Global Baking and Snacking; International Simple Meals and Beverages; U.S. Beverages; and Bolthouse and Foodservice segments.
Shares of Fortinet Inc (NASDAQ:FTNT), declined -3.04% to $40.86, during its last trading session.
Fortinet, declared that a number of K-12 school districts and educational institutions across the country are entrusting Fortinet and its partners with the security of their students, teachers and faculty in addition to their ability to take leaps forward with new technologies to enrich learning. Working with Fortinet, school districts in Hillsborough County, Florida; Merced County high school district in California; Cypress-Fairbanks ISD in Texas; in addition to Central Catholic High School in Pennsylvania, are now able to launch successful technologies and tools to expand the learning environment, while protecting important student and faculty data, and monitoring online activity via multiple devices to block actions that could be harmful to students or lead to a security compromise.
Fortinet, Inc. provides cyber security solutions for enterprises, service providers, and government organizations worldwide. The company offers FortiGate physical and virtual appliances products that provide various integrated security and networking functions to protect data, applications, and users from network- and content-level security threats; FortiManager product family to manage the system configuration and security functions of multiple FortiGate devices from a centralized console; and the FortiAnalyzer product family, which enables the collection, analysis, and archiving of content and log data generated by its products.
At the end of Tuesday’s trade, Shares of Gentex Corporation (NASDAQ:GNTX), lost -1.87% to $ 15.21.
Gentex Corporation declared that its Board of Directors declared a quarterly cash dividend of $0.085 (8.5 cents) per share that will be payable October 16, 2015, to shareholders of record of the common stock at the close of business on October 7, 2015.
Gentex Corporation designs, develops, manufactures, and markets automatic-dimming rearview mirrors and electronics for the automotive industry; dimmable aircraft windows for the aviation industry; and commercial smoke alarms and signaling devices for the fire protection industry worldwide.
Finally, Valeant Pharmaceuticals Intl Inc (NYSE:VRX), ended its last trade with -2.84% loss, and closed at $224.05.
Valeant Pharmaceuticals International declared that its associate has reached a partnership agreement with AstraZeneca under which Valeant was granted an exclusive license to develop and commercialize brodalumab.
Brodalumab is an IL-17 receptor monoclonal antibody in development for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. Under the agreement, Valeant will hold the exclusive rights to develop and commercialize brodalumab globally, except in Japan and certain other Asian countries where rights are held by Kyowa Hakko Kirin Co., Ltd under a preceding arrangement with Amgen Inc., the originator of brodalumab. Valeant will assume all development costs associated with the regulatory approval for brodalumab. Regulatory submission in EU and US for brodalumab in moderate-to-severe psoriasis is planned for the fourth quarter of 2015.
Under the terms of the agreement, Valeant will make an up-front payment to AstraZeneca of $100 million, in addition to additional pre-launch milestones of up to $170 million and further sales-related milestone payments of up to $175 million following launch. After approval, AstraZeneca and Valeant will share profits.
Valeant Pharmaceuticals International, Inc. develops manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
